Cybin Inc. Reports Strong Shareholder Participation in Annual Meeting with 48.92% Voting Representation

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, reported substantial shareholder participation in its annual meeting held August 18, 2025, with 90 shareholders representing 11,264,212 common shares accounting for 48.92% of the company's issued and outstanding common shares as of the record date. This level of engagement reflects strong investor interest in the company's progress toward developing next-generation mental healthcare treatments addressing significant unmet medical needs.

The company's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder. Cybin's approach focuses on developing intermittent treatments that provide long-lasting results, potentially revolutionizing mental health care delivery. The company maintains operational presence across multiple countries including Canada, the United States, the United Kingdom, the Netherlands and Ireland since its founding in 2019.

Investors can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN. The announcement was distributed through InvestorWire, a specialized communications platform that provides advanced wire-grade press release syndication services as part of the Dynamic Brand Portfolio @IBN, offering comprehensive corporate communications solutions including article syndication to over 5,000 outlets and social media distribution to millions of followers.